Preclinical data is positive but early-stage; the stock may see a short-term pop on the news, but the going concern risk and lack of near-term revenue catalyst limit upside. Monitor for next steps in PRF-110 development and any financing or partnership announcements.
Price Chart
Executive Summary
PRF Technologies (PRFX) announced positive preclinical results for its lead candidate PRF-110, showing sustained 72-hour analgesic activity comparable to the approved benchmark ZYNRELEF in a head-to-head pig study. The ropivacaine-only, NSAID-free formulation demonstrated comparable efficacy and a favorable safety profile. However, this is preclinical data only, and the company faces a going concern warning from its auditor, a history of losses, and a material weakness in internal controls, as noted in the prior 20-F filing.
Key Facts
- PRF-110 demonstrated sustained 72-hour analgesic activity comparable to ZYNRELEF in a head-to-head preclinical pig study.
- PRF-110 is a ropivacaine-only, NSAID-free formulation, potentially offering lower cardiac toxicity than bupivacaine.
- The company's auditor issued a going concern warning due to history of losses and uncertainty about future funding (per prior 20-F).
- PRF Technologies has a $1M market cap and 0% analyst bullish consensus.
- The company also has a dual business model including AI-driven energy optimization (DeepSolar).
Financial Impact
No financial figures provided in this filing. Prior 20-F reported net loss reduction from $14.6M to $4.8M and $4.1M cash.
Risk Factors
- Going concern risk and history of significant losses.
- Preclinical results may not translate to human clinical trials.
- Need for additional capital to fund operations and development.
- Material weakness in internal controls.
- Low market cap and analyst coverage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002898 |
| Document: zk2635415.htm | 0001178913-26-002898 |
| Document: 0001178913-26-002898-index-headers.html | 0001178913-26-002898 |
| Document: 0001178913-26-002898-index.html | 0001178913-26-002898 |
| Document: 0001178913-26-002898.txt | 0001178913-26-002898 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7390 (−0.14%) |
Oct 23, 2026 3d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7390 (−0.14%) |
Sep 28, 2026 28d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7390 (−23.97%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7390 (−24.34%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7390 (−26.83%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7390 (+23.66%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7390 (−24.53%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7390 (−24.53%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7390 (−32.20%) |
Jul 21, 2026 13w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7390 (−38.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers